Candid Therapeutics, Inc. announced that it expects to receive $505.508 million in funding from a group of investors

Candid Therapeutics, Inc. announced that it has entered into a subscription agreement for common shares for gross proceeds of $505,508,000 on March 1, 2026. The transaction included participation from a syndicate of leading healthcare institutional investors and mutual funds, including new investors, Venrock Healthcare Capital Partners Fund, L.P., a fund managed by Venrock Management, LLC, RA Capital Management, L.P., Janus Henderson Investors US LLC, accounts advised by T. Rowe Price Group, Inc., Viking Global Investors LP, Cormorant Asset Management, LP, Vivo Capital, LLC, and returning investors, venBio LLC, Foresite Capital Management, LLC, Soleus Capital Management, L.P., TCG Crossover Management, LLC, a life sciences focused institutional investor, several additional mutual funds and other institutional investors. The financing is expected to close immediately prior to the Merger.

The shares to be issued in the concurrent financing will be issued in private placements exempt from registration under Section 4(a)(2) of the Securities Act, and/or Regulation D promulgated thereunder.